Citations

Showing 10 of 108152 citations.

Statin therapy: does sex matter?
Kapoor, Ekta , Moyer, Ann M. , Hodis, Howard N., Miller, Virginia M. , Faubion, Stephanie S. , Kapoor, Ekta

Mayo Clinic

Menopause | September 11, 2019 | Volume: 26 | Issue: 12 | Pages: 1425-1435

10.1097/gme.0000000000001412 | PMID 31513091 Get It

Abstract Objective: Statins are a class of drugs that competitively bind to the active site of HMG-CoA reductase enzyme, thereby inhibiting the initial steps in cholesterol synthesis. Originally approved for use in lowering serum cholesterol, a risk factor for developing atherosclerosis and coronary heart disease, statins have subsequently been noted to have myriad extrahepatic effects, including potential effects on cognition, diabetes, breast cancer, bone, and muscle. This narrative review assesses the current state of the science regarding the risks and benefits of statin therapy in women to identify areas where additional research is needed. Methods: Basic and clinical studies were identified by searching PubMed with particular attention to inclusion of female animals, women, randomized controlled trials, and sex-specific analyses. Results: Statin therapy is generally recommended to reduce the risk of cardiovascular disease. None of the current clinical guidelines, however, offer sex-specific recommendations for women due to lack of understanding of sex differences and underlying mechanisms of disease processes. In addition, conclusions regarding efficacy of treatments do not consider lipid solubility for the drug, dosing, duration of treatment, interactions with estrogen, or comorbidities. Pleiotropic effects of statins are often derived from secondary analysis of studies with cardiovascular events as primary outcomes. Conclusions: Many of the trials that have established the efficacy and safety of statins were conducted predominantly or entirely in men, with results extrapolated to women. Additional research is needed to guide clinical recommendations specific to women. Video Summary: http://links.lww.com/MENO/A462.
Accuracy of Accelerometers for Measuring Physical Activity and Levels of Sedentary Behavior in Children: A Systematic Review
Lynch, Brian , Kaufman, Tara K. , Rajjo, Tamim , Mohammed, Khaled , Kumar, Seema, Murad, M. Hassan , Gentile, Natalie, Koepp, Gabriel A., McCrady-Spitzer, Shelly , Levine, James A. , Lynch, Brian A , Rajjo, Tamim I, Gentile, Natalie E, Murad, M Hassan

Mayo Clinic

Journal of Primary Care & Community Health | September 11, 2019 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/2150132719874252 | PMID 31509061 Get It

Objectives: This systematic review evaluated the accuracy of triaxial and omnidirectional accelerometers for measuring physical activity and sedentary behavior in children. Design: Systematic review of the literature. Methods: We comprehensively searched several databases for studies published from January 1996 through June 2018 that reported diagnostic accuracy measures in children and adolescents (age 3-18 years) and compared accelerometers with energy expenditure using indirect calorimetry. Results: We included 11 studies that enrolled 570 participants. All studies used indirect calorimetry as the reference standard. Across the studies, median sensitivity ranged from 46% to 96% and median specificity ranged from 71% to 96%. Median area under the curve ranged from 69% to 98%. Conclusions: Accuracy measures were greatest when detecting sedentary behavior and lowest when detecting light physical activity. Accuracy was higher when the accelerometer was placed on the hip compared with the wrist. The current evidence suggests that triaxial and omnidirectional accelerometers are accurate in measuring sedentary behavior and physical activity levels in children.
Rural‐Urban Differences in Breast Reconstruction Utilization Following Oncologic Resection
DeCoster, Ryan , Bautista, Robert‐Marlo , Burns, Jack C., Edmunds, Robert , Rinker, Brian, Webster, J. Matthew , Vásconez, Henry C., DeCoster, Ryan C , Rinker, Brian D, Dugan, Adam Joseph

Mayo Clinic

The Journal of Rural Health | September 11, 2019 | Volume: 36 | Issue: 3 | Pages: 347-354

10.1111/jrh.12396 | PMID 31508853 Get It

AbstractBackgroundBreast reconstruction (BR) is the reconstructive surgical technique that focuses on restoring normal form and function to the breast following oncologic resection. The goal of this study was to determine if BR disparities exist among rural female patients in Kentucky.MethodsA retrospective (2006‐2015), population‐based cohort study was conducted on breast cancer patients (stages I‐III) treated with mastectomy with or without BR. We used 2013 Beale codes to stratify patients according to geographic status. Chi‐square tests were used to examine the association of BR along the rural‐urban continuum. A multivariate logistic regression model controlling for patient, disease, and treatment factors was used to predict BR. The likelihood of BR was reported in odds ratios (OR) using a 95% confidence interval (CI).ResultsOverall, 10,032 patients met study criteria. Of those, 2,159 (21.5%) underwent BR. The rate of BR among urban, near‐metro, and rural patients was 31.1%, 20.4%, and 13.4%, respectively (P < .001). Multivariate analysis revealed that women from near metro (OR 0.54, CI: 0.47‐0.61; P < .001) and rural areas (OR 0.36, CI: 0.31‐0.41; P < .001) were less likely to undergo BR than women from urban areas.ConclusionAlthough BR benefits are well documented, women from rural Kentucky undergo BR at lower rates and are less likely to receive BR than their urban counterparts. Efforts should seek to promote equitable access to BR for all patients, including those from rural areas.
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
Chow, Warren , Frankel, Paul , Ruel, Chris , Araujo, Dejka M. , Milhem, Mohammed , Okuno, Scott H. , Hartner, Lee , Undevia, Samir D., Staddon, Arthur P., Milhem, Mohammed M , Chow, Warren A

Mayo Clinic

Cancer | September 11, 2019 | Volume: 126 | Issue: 1 | Pages: 105-111

10.1002/cncr.32515 | PMID 31509242 Get It

Background This single‐arm, multicenter, phase 2 study evaluated the safety and antitumor activity of pazopanib in patients with unresectable or metastatic conventional chondrosarcoma. Methods Eligible patients had conventional chondrosarcoma of any grade with measurable tumors that were unresectable or metastatic. Patients with mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes and patients who received prior tyrosine kinase inhibitor therapy were excluded. Pazopanib at 800 mg once daily was administered for 28‐day cycles. Tumor responses were evaluated by local radiology assessments every 2 cycles. The primary endpoint was the disease control rate (DCR) at week 16 (4 cycles). Results Forty‐seven patients were enrolled. The DCR at 16 weeks was 43% (95% confidence interval [CI], 28%‐58%), which was superior to the null hypothesis rate of 30%, but the 2‐sided P value (exact test) was .09 (1‐sided P = .045). One patient had a partial response. The median overall survival was 17.6 months (95% CI, 11.3‐35.0 months), and the median progression‐free survival was 7.9 months (95% CI, 3.7‐12.6 months). Grade 3 or higher adverse events were infrequent; hypertension (26%) and elevated alanine aminotransferase (9%) were most common. Conclusions This study provides evidence of positive drug activity for pazopanib in conventional chondrosarcoma.
Online Migraine Education and Support for Patients: Perspectives from the American Headache Society Emerging Leaders Program
VanderPluym, Juliana H. , Hamilton, Katherine , Hindiyeh, Nada , Robbins, Matthew S. , Starling, Amaal J. , Vargas, Bert B., Gibbons, Sarah K., Vgontzas, Angeliki , Robbins, Matthew S , Gibbons, Sarah K., VanderPluym, Juliana

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 11, 2019 | Volume: 59 | Issue: 9 | Pages: 1656-1658

10.1111/head.13649 | PMID 31508808 Get It

Hemodynamic assessment in heart failure
Jain, C. Charles , Borlaug, Barry A. , Jain, Christopher Charles, Borlaug, Barry A

Mayo Clinic

Catheterization and Cardiovascular Interventions | September 11, 2019 | Volume: 95 | Issue: 3 | Pages: 420-428

10.1002/ccd.28490 | PMID 31507065 Get It

AbstractHemodynamics play a central role in the pathophysiology of heart failure (HF), yet their proper assessment and optimization remains challenging. Heart failure is defined as the inability of the heart to deliver adequate perfusion (cardiac output) to the body at rest or exercise, or to require an elevation in cardiac filling pressures in order to do this. This bedrock definition is important because it relies on measurable quantities (filling pressures and output) that are readily assessed in the cardiac catheterization laboratory. Here we present three cases to illustrate how better understanding of the determinants of cardiac output and stroke volume: preload, afterload, contractility, and lusitropy, as well as the determinants of congestion (high filling pressures) may be used to guide optimization of hemodynamic status. The goal is that the readers will be able to think more critically when evaluating the hemodynamics of their patient in HF and recognize the complex interplay that determines the complex balance between cardiac ejection and filling capabilities, and how this alters symptoms and outcomes for patients with HF.Key Points Careful assessment of hemodynamics in the catheterization laboratory allows for actionable insight to a patient's volume status, cardiac function and can help prognosticate outcomes. Exercise hemodynamics in heart failure is a powerful tool to better understand the cause of symptoms and predict outcomes. Clinicians should aim to decrease biventricular filling pressures to normal values to improve morbidity and reduce risk for readmission. In patients with heart failure and reduced ejection fraction, clinicians should aim to decrease afterload as much as can be tolerated by the renal function and patient's symptoms. Low cardiac output can often be improved by optimizing preload and afterload rather than initiating inotropes, which should be reserved until needed. In advanced heart failure, the right heart function becomes a key determinant of symptoms and outcomes.
High Cervical Intrathecal Targeted Drug Delivery: A Case Report of Refractory Oropharyngeal Cancer Pain
Rogers, Julie M.G. , Pittelkow, Thomas P. , Moman, Rajat N. , Rogers, Julie M , Pittelkow, Thomas P

Mayo Clinic

Case Reports in Oncological Medicine | September 10, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-3

10.1155/2019/2098921 | PMID 31583144 Get It

Introduction. Some patients with head and neck cancers have pain refractory to aggressive multimodal therapies. Herein, we report the use of an intrathecal targeted drug delivery (TDD) system catheter tip placed at C1 for the treatment of recalcitrant oropharyngeal cancer pain. Case Report. A patient with recurrent metastatic squamous cell tongue cancer reported severe pain not controlled despite high-dose opioids and nonopioid adjuvants. It was elected to proceed with an intrathecal TDD system with the catheter tip placed at the C1 level. After pump placement, we were able to decrease her daily oral morphine equivalents (OME) from nearly 1000 mg to 300 mg over the course of two months while titrating her TDD from 0.3 mg/day to 0.7 mg/day of intrathecal hydromorphone. Unfortunately, her improvement was limited secondary to aggressive cancer-directed treatments likely contributing to device infection and explant. Conclusions. In this patient, high cervical placement of an intrathecal TDD catheter was associated with a decrease in OME. While used in clinical practice on occasion, the use of high cervical TDD placement such as this implantable C1 intrathecal TDD system for cancer-associated pain is underreported in the literature. Further studies on this intervention within this challenging population are warranted.
Pilot testing an app-based stress management intervention for cancer survivors
Børøsund, Elin , Clark, Matthew M. , Ehlers, Shawna L. , Andrykowski, Michael A. , Sleveland, Hilde Renate Sætre, Bergland, Anne , Nes, Lise Solberg , Børøsund, Elin , Varsi, Cecilie

Mayo Clinic

Translational Behavioral Medicine | September 10, 2019 | Volume: 10 | Issue: 3 | Pages: 770-780

10.1093/tbm/ibz062 | PMID 31330023 Get It

Abstract Psychosocial eHealth intervention programs for cancer survivors are still in their infancy, with inconsistent findings so far in the scientific literature. The aim of this study was to explore system use, usefulness, ease of use, and preliminary effects of Stress Proffen, an app-based cognitive-behavioral stress management intervention for patients with cancer. A feasibility pilot project tested the intervention with cancer survivors (N = 25). The intervention contained (a) one face-to-face introduction session, (b) 10 app-based modules with stress management educational material and exercises, and (c) one follow-up phone call. Post-intervention interviews were conducted and user log-data were extracted. Outcome measures—Perceived Stress Scale (PSS), Anxiety and Depression (Hospital Anxiety and Depression Scale [HADS]), Health-Related Quality of Life (HRQoL; SF-36), and Self-Regulatory Fatigue (SRF-18)—were completed at baseline and post-intervention. Participants were primarily women (84%), age 34–71 (mean 48) and represented a variety of cancer diagnoses (majority breast cancer: 40%). Twenty-two participants completed all (pre–post) questionnaires. Sixteen participants (67%) completed at least 7 of 10 modules within the 8-week study period. Post-intervention interviews described StressProffen as providing a new, appreciated, and easily accessible stress management tool for the cancer survivors. Dependent/paired t-tests showed significant pre–post intervention effects with significant decrease in stress (p = .008), anxiety (p = .019), and self-regulatory fatigue (p = .025), and improved HRQoL (Role Physical, General Health, Vitality, and Role Emotional, all p’s &lt;.01). App-based stress management interventions such as StressProffen can provide appreciated support for cancer survivors, should be easy to use, can provide significant stress reduction, and improve emotional well-being. Further testing in a randomized controlled trial is warranted and is in progress. Clinicaltrials.gov: NCT0293961.
CKD: A Call for an Age-Adapted Definition
Delanaye, Pierre , Jager, Kitty J. , Christensson, Anders , Dubourg, Laurence , Eriksen, Björn O. , Gaillard, F. , Gambaro, Giovanni , Giet, Markus van der , Glassock, Richard J. , Indridason, Ólafur S. , Londen, Marco van , Mariat, Christophe , Melsom, Toralf , Pottel, Hans , Schäeffner, Elke , Taal, Maarten W. , White, Christine A. , Grubb, Anders , Christensson, Anders , Eriksen, Bjørn Odvar , Nordin, Gunnar , Rule, Andrew D , Taal, Maarten W , Grubb, Anders , Delanaye, Pierre , Gaillard, Francois , Schaeffner, Elke , van Londen, Marco , Bökenkamp, Arend , Moranne, Olivier P. , Nordin, Gunnar , Pálsson, Runólfur , Rule, Andrew D. , Brand, Jan A.J.G. van den , Jager, Kitty J

Mayo Clinic

Journal of the American Society of Nephrology | September 10, 2019 | Volume: 30 | Issue: 10 | Pages: 1785-1805

10.1681/asn.2019030238 | PMID 31506289 Get It

Current criteria for the diagnosis of CKD in adults include persistent signs of kidney damage, such as increased urine albumin-to-creatinine ratio or a GFR below the threshold of 60 ml/min per 1.73 m 2 . This threshold has important caveats because it does not separate kidney disease from kidney aging, and therefore does not hold for all ages. In an extensive review of the literature, we found that GFR declines with healthy aging without any overt signs of compensation (such as elevated single-nephron GFR) or kidney damage. Older living kidney donors, who are carefully selected based on good health, have a lower predonation GFR compared with younger donors. Furthermore, the results from the large meta-analyses conducted by the CKD Prognosis Consortium and from numerous other studies indicate that the GFR threshold above which the risk of mortality is increased is not consistent across all ages. Among younger persons, mortality is increased at GFR <75 ml/min per 1.73 m 2 , whereas in elderly people it is increased at levels <45 ml/min per 1.73 m 2 . Therefore, we suggest that amending the CKD definition to include age-specific thresholds for GFR. The implications of an updated definition are far reaching. Having fewer healthy elderly individuals diagnosed with CKD could help reduce inappropriate care and its associated adverse effects. Global prevalence estimates for CKD would be substantially reduced. Also, using an age-specific threshold for younger persons might lead to earlier identification of CKD onset for such individuals, at a point when progressive kidney damage may still be preventable.
Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging
Adler, Charles H. , Beach, Thomas G. , Shill, Holly A. , Driver‐Dunckley, Erika , Caviness, John N., Mehta, Shyamal H. , Sue, Lucia I., Belden, Christine M. , Powell, Jessica, Jacobson, Sandra A. , Zamrini, Edward , Shprecher, David , Davis, Kathryn, Dugger, Brittany N. , Hentz, Joseph G. , Driver-Dunckley, Erika, Adler, C H , Shprecher, David , Dugger, Brittany N , Zhang, Nan , Sabbagh, Marwan Noel , Serrano, Geidy E.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | September 10, 2019 | Volume: 78 | Issue: 10 | Pages: 891-899

10.1093/jnen/nlz080 | PMID 31504679 Get It

Abstract This study was designed to correlate clinical findings with the extent of pathologic a-synuclein (aSyn) in the brain using the Unified Staging System for Lewy Body disorders (USSLB). Data from 280 cases from the Arizona Study of Aging and Neurodegenerative Disorders are presented. Each case had a complete USSLB staging and at least 1 full research clinical assessment, including subspecialty neurologist-administered movement and cognitive evaluation. Of the 280, 25.7% were cognitively normal, 8.6% had mild cognitive impairment, and 65.7% had dementia. All cases could be categorized into 1 of 5 USSLB stages (8.6% stage I—olfactory bulb only; 15.4% IIa—brainstem predominant; 13.6% IIb—limbic predominant; 31.8% III—brainstem and limbic; and 30.7% IV—neocortical) yet using the Braak staging system 70 cases (25.3%) could not be classified. Those with USSLB stages III and IV died at a younger age. Multiple measures of motor parkinsonism, cognitive impairment, hyposmia, and probable RBD were significantly correlated with increasing USSLB stage. We conclude that the USSLB is the most comprehensive staging system for all Lewy body disorders and allows for categorization and ranking of all brains with significant correlations to many motor and nonmotor clinical signs and symptoms.